<DOC>
	<DOC>NCT01705704</DOC>
	<brief_summary>This retrospective study will evaluate the association of biomarkers and the treatment response of patients with chronic hepatitis B, who have completed therapy with Pegasys (peginterferon alfa-2a) ± lamivudine. For the analysis stored serum samples obtained from patients will be used; no actual patients are involved.</brief_summary>
	<brief_title>A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>Patients with HBeantigen positive or negative chronic hepatitis B, and no other chronic viral infections who completed therapy for Hepatitis B with Pegasys ± lamivudine Inclusion criteria relevant to the clinical studies WV16240, WV16241, and Neptune/WV19432 Samples from patients treated with either Pegasys or Pegays + lamivudine are included in this analytical study Samples will only be analyzed for patients where Investigational Review Board approval has been granted Exclusion criteria relevant to the clinical studies WV16240, WV16241, and Neptune/WV19432</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>